Business Context and Reporting Period
Company: Bone Biologics Corp (BBLG)
Filing Type: Form 8-K (Current Report)
Date of Report: June 25, 2025
Reporting Period: Event date June 25, 2025; Press release issued June 26, 2025.
Business Context: The Company is a Delaware corporation with principal executive offices in Burlington, MA. Its common stock and warrants trade on the Nasdaq Capital Market.
Key Financial Metrics
This filing is a Current Report on Form 8-K regarding a corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
Regulatory Compliance: The Company received confirmation from the Listing Qualifications Department of The Nasdaq Stock Market LLC on June 25, 2025, that it has regained compliance with Nasdaq Listing Rule 5550(a)(2). This rule requires listed companies to maintain a minimum bid price of at least $1 per share.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) announcing the restoration of compliance with Nasdaq listing standards. No forward-looking guidance, financial outlook, or specific risk factors are detailed within the text of this 8-K filing.
Investor Verification Checklist
- Verify the current trading price of BBLG common stock to confirm sustained compliance with the $1.00 minimum bid price requirement.
- Review the full text of the press release filed as Exhibit 99.1 for additional context on the compliance timeline.
- Check subsequent filings for any updates regarding the Company's financial position or operational milestones.